Description: NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its two lead product candidates, include Quilience, for the treatment of excessive daytime sleepiness and cataplexy; and Nolazol, for the treatment of ADHD. NLS Pharmaceutics AG was founded in 2015 and is based in Stans, Switzerland.
Home Page: nlspharma.com
NLSP Technical Analysis
The Circle 6
Zurich,
8058
Switzerland
Phone:
41 44 512 21 50
Officers
| Name | Title |
|---|---|
| Mr. Alexander Zwyer M.B.A. | Pres, CEO & Director |
| Mr. Chad C. Hellmann M.B.A. | Chief Financial Officer |
| Mr. Eric Konofal M.D., Ph.D. | Chief Scientific Officer |
| Dr. Christian C. Wenger Dr. iur., L.L.M., LL.M., Ph.D. | Gen. Counsel |
| Ms. Sharon Keys | Head of Regulatory Affairs |
| Dr. George Apostol M.D. | Chief Medical Officer and Global Head of R&D |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 25.7772 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-01-29 |
| Fiscal Year End: | December |
| Full Time Employees: | 6 |